Samsung Biologics under pressure amid labor dispute and failed ADC deal
Concerns are mounting that last year’s failed antibody-drug conjugate (ADC) order at Samsung Biologics could be repeated this year, as the company faces renewed labor tensions following an internal personal data leak.President and CEO John Rim has been meeting the labor union every one to two weeks in an effort to break the deadlock. However, key issues — i..